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PreviewsThe Power of the Dark Side:
Huntington’s Disease Protein
and p53 Form a Deadly Alliance
A role for apoptotic mediators in neurodegenerative
disease has long been considered, but the identity of
the putative effectors and the basis of their actions
in neurodegeneration remain ill-defined. Huntington’s
disease (HD) is a polyglutamine disorder whose path-
ogenesis likely involves mitochondrial dysfunction.
In this issue of Neuron, Bae et al. present data impli-
cating p53 in HD pathogenesis. This intriguing study
may thus provide a link between nuclear transcription
dysregulation and mitochondrial abnormalities in HD.
A major challenge in the study of neurodegenerative
disease is to reconcile the gradual process of neuronal
dysfunction with the rapid nature of classic pro-
grammed cell death pathways proposed to account for
neuronal loss. Indeed, while there is considerable evi-
dence for activation of apoptotic pathways and media-
tors of apoptosis in Alzheimer’s disease, Parkinson’s
disease, amyotrophic lateral sclerosis, and Hunting-
ton’s disease (HD) (Yuan and Yankner, 2000), sorting out
the relative roles of the different players has been a
complicated task. For the polyglutamine (polyQ) disor-
ders, of which HD has been the most extensively
studied, much of the work has focused upon recruit-
ment of downstream mediators (caspases) and how
their activation promotes polyQ neurodegeneration.
Thus, an elusive question has been the identity of the
upstream mediators and the nature of their actions. In
this issue of Neuron, a research group led by Dr. Akira
Sawa provides compelling evidence of a role for p53 in
HD pathogenesis in a study that attempts to link HD’s
nuclear pathology with its pronounced mitochondrial
abnormalities (Bae et al., 2005).
HD is one of nine inherited polyQ diseases charac-
terized by the production of an abnormally folded pro-
tein that exerts its toxicity in large part through a gain-
of-function effect upon cellular pathways (Zoghbi and
Orr, 2000). Each polyQ disorder varies in its pattern of
neuronal dysfunction, despite widespread overlapping
expression of the different disease proteins throughout
the central nervous system. HD displays autosomal-
dominant inheritance, and affected patients typically
present in adulthood with involuntary dance-like move-
ments that progress to involve severe cognitive decline.
The disorder worsens over the course of 10–25 years,
until patients ultimately succumb to the disease. At pre-
sent, there are no effective treatments. For many of the
polyQ diseases, the misfolded polyQ-expanded protein
cannot be efficiently degraded and traffics to the nu-
cleus where it accumulates to form inclusion bodies.
Since amino-terminal proteolytic cleavage of the HD
polyQ disease protein is well documented, HD cell cul-
ture and animal models often employ such amino-ter-
minal truncated proteins, as this typically acceleratesthe pathogenic cascade and facilitates dissection of
the involved pathways.
In the Bae et al. study, the authors hypothesized that
p53 might be involved in HD and proceeded to test this
hypothesis. The rationale for their choice of p53 de-
serves consideration. p53 is an extremely important
protein—a classic tumor suppressor poised to respond
to a variety of cellular stresses that occur in abnormal
cells, and upon detection of the cellular stress, initiate
a series of events that either rectifies the problem or
culminates in apoptosis (Vousden, 2000). The impor-
tance of p53's anticancer function in cycling cells is
well established. Indeed, inherited heterozygous muta-
tion of p53 predisposes to Li-Fraumeni syndrome, a
disorder characterized by multiple independent primary
malignancies typically beginning in childhood or ado-
lescence. Although mostly studied in the context of
cancer, recognition that p53 is a central factor in cellu-
lar stress response has brought it to the attention of
neuroscientists. Elevated p53 has been detected in
brain tissue from patients diagnosed with neurodegen-
erative diseases. For example, patients with Alzheim-
er’s disease show increased p53 immunoreactivity in
morphologically damaged neurons, consistent with the
presence of increased p53 in neurons from mice over-
expressing β-amyloid peptide (Aβ-1-42) (LaFerla et al.,
1996). Motor neuron degeneration observed in amyo-
trophic lateral sclerosis has been associated with in-
creased levels of p53 in motor neurons of the spinal
cord and motor cortex (Martin, 2000).
The p53 tumor suppressor is a sequence-specific
transcription factor that induces a biological response
largely through the transactivation of specific target
genes, although it also possesses repressor activity.
Besides its well-described transactivation-dependent
effects, p53 may regulate apoptosis through transacti-
vation-independent pathways, although the basis of
such effects remains controversial (Schuler and Green,
2005). Regardless of its mode of action, the net result
of p53 activation is to alter the permeability of the outer
mitochondrial membrane. The ability of p53 to induce
mitochondrial dysfunction made it an appealing candi-
date for involvement in HD, since numerous lines of in-
dependent investigation have consistently pinpointed
the mitochondria as a prominent target in disease
pathogenesis. In 1993, it was reported that chronic ad-
ministration of a mitochondrial toxin, 3-nitopropionic
acid, resulted in a selective loss of medium spiny neu-
rons in the striatum (Beal et al., 1993). Follow-up studies
performed upon HD patient material have documented
significant reductions in the enzymatic activities of
complexes II, III, and IV of the mitochondrial oxidative
phosphorylation pathway in caudate and putamen—
the regions of the brain principally affected in HD, while
not detecting such alterations in HD cerebellum or fi-
broblasts (Tabrizi et al., 1999). These provocative find-
ings suggest that mitochondrial dysfunction may con-
tribute to HD pathogenesis and could perhaps account
for the cell-type specificity in this neurodegenerative
disorder.
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2The Sawa group began its evaluation of p53 by deter-
mining if mutant huntingtin protein (mHtt) affected p53
metabolism and function (Bae et al., 2005). They found
evidence for a direct interaction between Htt and p53
and observed a striking upregulation of p53 protein
levels both in PC12 cells expressing mutant Htt and in
the brains of HD transgenic mice. Brain regions in HD
patients showing elevated levels of p53 matched the
regional and cellular selectivity of HD neuropathology.
The authors demonstrated that the Htt-p53 binding in-
teraction was enhanced by expansion of the polyQ
tract and noted increased p53 promoter-reporter acti-
vation in the presence of polyQ-expanded Htt in both
PC12 cells and primary cortical neurons. Several down-
stream targets of p53, Bax and PUMA, were upregu-
lated in PC12 cells expressing Htt. They next examined
the functional consequences of the Htt-p53 interaction
by measuring mitochondrial membrane depolarization
Fin their PC12 cell model, in HD patient lymphoblasts,
tand in p53 null primary cortical neurons transfected
Iwith Htt expression constructs. These studies yielded
idramatic evidence for the role of p53 in producing mito-
dchondrial membrane abnormalities, as treatment of
H
PC12 cells and patient lymphoblasts with the p53 inhib- w
itor pifithrin-α rescued depolarization in each experi- r
ment and absence of p53 was completely protective. w
pBae et al. then chose to evaluate the effects of p53 in
itwo animal models of HD—a Drosophila model and the
lN171 mouse model—by crossing the HD flies and mice
w
onto a p53 null genetic background. In both cases, they l
documented significant amelioration of the neurode- p
generative phenotype. By presenting such a broad d
tportfolio of consistent experimental results, the authors
vmade a convincing case that p53 is involved in HD dis-
tease progression (Figure 1).
nAs compelling as the Bae et al. study is, many unan-
swered questions regarding the role of p53 in HD and
more broadly in other neurological diseases remain.
i
Bae et al.’s observation of a direct binding interaction
abetween Htt and p53 corroborates previous work (Stef-
afan et al., 2000). In the earlier study, however, polyQ-
mexpanded Htt repressed transcription in a p53-depen-
edent and p53-independent manner. As the authors of
tthe current study point out, such Htt-mediated repres-
bsion may reflect the use of a nonneuronal cell line, al-
pthough Htt-mediated repression of p53-regulated pro-
moters was also observed in differentiated PC12 cells
cin that study (Steffan et al., 2000). One intriguing aspect
pof the Bae et al. work is the pronounced upregulation
hof p53 levels in HD cells, and their finding that this is
coccurring not at the level of transcription but likely
nposttranslationally. What might the basis of this be? If
dthe effect is specific to HD, then it should not result
dfrom a general impairment of ubiquitin-proteasome
tfunction (assumed to be a common feature of polyQ
ndiseases), although Htt binding to p53 could selectively
yalter p53 interactions with molecules such as MDM2, a
akey regulator of p53 degradation. Consequently, identi-
pfication of the protein domains that mediate binding be-
ctween p53 and Htt could have therapeutic implications
lfor disrupting p53 activation in HD, especially since
oknocking down p53 is likely to be laden with too many
spotentially dangerous side effects to be feasible. An-
other issue that deserves consideration is the specific- aigure 1. A Model for the Pathway and Action of p53 in Hunting-
on’s Disease
n the Bae et al. study, the authors hypothesized that p53 might be
nvolved in linking the nuclear pathology of HD with mitochondrial
ysfunction. They found evidence for a direct interaction between
tt and p53 and demonstrated that the Htt-p53 binding interaction
as enhanced with expansion of the polyQ tract (Htt-polyQ). Their
esults support a role for p53 activation in HD pathogenesis. Here
e see a model outlining the potential pathways by which Htt-
olyQ activation of p53 may result in mitochondrial dysfunction. As
ncreased p53 promoter-reporter activation in the presence of po-
yQ-expanded Htt in both PC12 cells and primary cortical neurons
as noted and several downstream targets of p53 were upregu-
ated in Htt-expressing PC12 cells, interaction of Htt-polyQ with
53 likely produces mitochondrial abnormalities in a transcription-
ependent fashion. p53 may also promote mitochondrial dysfunc-
ion through a transcription-independent pathway that could in-
olve a direct action at the mitochondrial outer membrane, al-
hough evidence for such an effect in the Bae et al. study was
ot found.ty of p53 involvement in HD pathogenesis. While the
uthors show that polyQ-expanded ataxin-1 does not
ffect p53 transactivation and an earlier study of p53
odulation of SCA1 disease in mice yielded moderate
ffects upon Purkinje cell morphology but without func-
ional improvement or increased cellular survival (Shah-
azian et al., 2001), the role of p53 as a modifier in other
olyQ diseases should be more carefully evaluated.
Finally, Bae et al. document impaired mitochondrial
omplex IV function in HD transgenic mice, which was
artially restored by systemic treatment with a p53 in-
ibitor. It is presently unknown if p53 can disrupt mito-
hondrial function in the absence of apoptosis in non-
euronal cells, but this finding suggests that p53 can
o so in neurons, since neuronal cell death is not evi-
ent in this mouse model. Further studies investigating
he basis of this effect, perhaps focusing on coordi-
ately upregulated downstream targets of p53, may
ield insights into how this is occurring. These results
lso raise another important question: how could p53
romote neuronal dysfunction but not apoptosis in the
ontext of neurodegeneration? One possibility may re-
ate to the finding that p53 is required for the induction
f caspase activity following genotoxic damage (John-
on et al., 1999). Sublethal accumulation of DNA dam-
ge resulting from chronic oxidative stress could acti-
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3vate p53 to a level that promotes the transcription of
genes that are required for the localized activation of
caspases in axons or dendrites subjected to extensive
stimulation by excitatory neurotransmitters. This might
lead to localized “synaptic cell death” and dendritic
thinning. p53 is reportedly present in synapses where it
has been suggested to mediate mitochondrial dysfunc-
tion and synaptic degeneration in response to DNA
damage, oxidative stress, and excitotoxic insults (Gil-
man et al., 2003). Clearly, additional studies will be re-
quired to fully evaluate the role of p53 in HD and other
neurological disorders, since other disease proteins may
find the draw of p53’s dark side impossible to resist.
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